198 related articles for article (PubMed ID: 28550180)
21. Identification of a novel de novo mutation associated with PRKAG2 cardiac syndrome and early onset of heart failure.
Liu Y; Bai R; Wang L; Zhang C; Zhao R; Wan D; Chen X; Caceres G; Barr D; Barajas-Martinez H; Antzelevitch C; Hu D
PLoS One; 2013; 8(5):e64603. PubMed ID: 23741347
[TBL] [Abstract][Full Text] [Related]
22. The insulin-induced signalling pathway leading to S6 and initiation factor 4E binding protein 1 phosphorylation bifurcates at a rapamycin-sensitive point immediately upstream of p70s6k.
von Manteuffel SR; Dennis PB; Pullen N; Gingras AC; Sonenberg N; Thomas G
Mol Cell Biol; 1997 Sep; 17(9):5426-36. PubMed ID: 9271419
[TBL] [Abstract][Full Text] [Related]
23. Severe hypertrophic cardiomyopathy in an infant with a novel PRKAG2 gene mutation: potential differences between infantile and adult onset presentation.
Kelly BP; Russell MW; Hennessy JR; Ensing GJ
Pediatr Cardiol; 2009 Nov; 30(8):1176-9. PubMed ID: 19787389
[TBL] [Abstract][Full Text] [Related]
24. [Effects and mechanism of glycine on rat cardiomyocytes pretreated with serum from burned rats].
Lyu SJ; Yan ZD; Fan RH; Peng X
Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi; 2023 May; 39(5):434-442. PubMed ID: 37805752
[No Abstract] [Full Text] [Related]
25. Inhibition of insulin signaling and adipogenesis by rapamycin: effect on phosphorylation of p70 S6 kinase vs eIF4E-BP1.
El-Chaâr D; Gagnon A; Sorisky A
Int J Obes Relat Metab Disord; 2004 Feb; 28(2):191-8. PubMed ID: 14970836
[TBL] [Abstract][Full Text] [Related]
26. Luteinizing hormone stimulates mammalian target of rapamycin signaling in bovine luteal cells via pathways independent of AKT and mitogen-activated protein kinase: modulation of glycogen synthase kinase 3 and AMP-activated protein kinase.
Hou X; Arvisais EW; Davis JS
Endocrinology; 2010 Jun; 151(6):2846-57. PubMed ID: 20351317
[TBL] [Abstract][Full Text] [Related]
27. AMP activated protein kinase-alpha2 deficiency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction in mice.
Zhang P; Hu X; Xu X; Fassett J; Zhu G; Viollet B; Xu W; Wiczer B; Bernlohr DA; Bache RJ; Chen Y
Hypertension; 2008 Nov; 52(5):918-24. PubMed ID: 18838626
[TBL] [Abstract][Full Text] [Related]
28. Activation of cardiac hypertrophic signaling pathways in a transgenic mouse with the human PRKAG2 Thr400Asn mutation.
Banerjee SK; McGaffin KR; Huang XN; Ahmad F
Biochim Biophys Acta; 2010 Feb; 1802(2):284-91. PubMed ID: 20005292
[TBL] [Abstract][Full Text] [Related]
29. Pioglitazone, a PPARγ agonist, attenuates PDGF-induced vascular smooth muscle cell proliferation through AMPK-dependent and AMPK-independent inhibition of mTOR/p70S6K and ERK signaling.
Osman I; Segar L
Biochem Pharmacol; 2016 Feb; 101():54-70. PubMed ID: 26643070
[TBL] [Abstract][Full Text] [Related]
30. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
Han S; Khuri FR; Roman J
Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245
[TBL] [Abstract][Full Text] [Related]
31. Cardiovascular magnetic resonance findings in patients with PRKAG2 gene mutations.
Pöyhönen P; Hiippala A; Ollila L; Kaasalainen T; Hänninen H; Heliö T; Tallila J; Vasilescu C; Kivistö S; Ojala T; Holmström M
J Cardiovasc Magn Reson; 2015 Oct; 17():89. PubMed ID: 26496977
[TBL] [Abstract][Full Text] [Related]
32. Exendin-4 attenuates cardiac hypertrophy via AMPK/mTOR signaling pathway activation.
Zhou Y; He X; Chen Y; Huang Y; Wu L; He J
Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):394-9. PubMed ID: 26519882
[TBL] [Abstract][Full Text] [Related]
33. CRISPR correction of the PRKAG2 gene mutation in the patient's induced pluripotent stem cell-derived cardiomyocytes eliminates electrophysiological and structural abnormalities.
Ben Jehuda R; Eisen B; Shemer Y; Mekies LN; Szantai A; Reiter I; Cui H; Guan K; Haron-Khun S; Freimark D; Sperling SR; Gherghiceanu M; Arad M; Binah O
Heart Rhythm; 2018 Feb; 15(2):267-276. PubMed ID: 28917552
[TBL] [Abstract][Full Text] [Related]
34. Glycogen storage diseases presenting as hypertrophic cardiomyopathy.
Arad M; Maron BJ; Gorham JM; Johnson WH; Saul JP; Perez-Atayde AR; Spirito P; Wright GB; Kanter RJ; Seidman CE; Seidman JG
N Engl J Med; 2005 Jan; 352(4):362-72. PubMed ID: 15673802
[TBL] [Abstract][Full Text] [Related]
35. Activation of AMPK and inactivation of Akt result in suppression of mTOR-mediated S6K1 and 4E-BP1 pathways leading to neuronal cell death in in vitro models of Parkinson's disease.
Xu Y; Liu C; Chen S; Ye Y; Guo M; Ren Q; Liu L; Zhang H; Xu C; Zhou Q; Huang S; Chen L
Cell Signal; 2014 Aug; 26(8):1680-1689. PubMed ID: 24726895
[TBL] [Abstract][Full Text] [Related]
36. Molecular cross-talk between MEK1/2 and mTOR signaling during recovery of 293 cells from hypertonic stress.
Naegele S; Morley SJ
J Biol Chem; 2004 Oct; 279(44):46023-34. PubMed ID: 15292274
[TBL] [Abstract][Full Text] [Related]
37. Increased alpha2 subunit-associated AMPK activity and PRKAG2 cardiomyopathy.
Ahmad F; Arad M; Musi N; He H; Wolf C; Branco D; Perez-Atayde AR; Stapleton D; Bali D; Xing Y; Tian R; Goodyear LJ; Berul CI; Ingwall JS; Seidman CE; Seidman JG
Circulation; 2005 Nov; 112(20):3140-8. PubMed ID: 16275868
[TBL] [Abstract][Full Text] [Related]
38. ANG II activates effectors of mTOR via PI3-K signaling in human coronary smooth muscle cells.
Hafizi S; Wang X; Chester AH; Yacoub MH; Proud CG
Am J Physiol Heart Circ Physiol; 2004 Sep; 287(3):H1232-8. PubMed ID: 15317677
[TBL] [Abstract][Full Text] [Related]
39. Integrative Analysis of PRKAG2 Cardiomyopathy iPS and Microtissue Models Identifies AMPK as a Regulator of Metabolism, Survival, and Fibrosis.
Hinson JT; Chopra A; Lowe A; Sheng CC; Gupta RM; Kuppusamy R; O'Sullivan J; Rowe G; Wakimoto H; Gorham J; Burke MA; Zhang K; Musunuru K; Gerszten RE; Wu SM; Chen CS; Seidman JG; Seidman CE
Cell Rep; 2016 Dec; 17(12):3292-3304. PubMed ID: 28009297
[TBL] [Abstract][Full Text] [Related]
40. Controversial molecular functions of CBS versus non-CBS domain variants of PRKAG2 in arrhythmia and cardiomyopathy: A case report and literature review.
Gong X; Yu P; Wu T; He Y; Zhou K; Hua Y; Lin S; Wang T; Huang H; Li Y
Mol Genet Genomic Med; 2022 Jul; 10(7):e1962. PubMed ID: 35588295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
